Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 10/2009

01-10-2009 | Editorial

Collateral damage: the conundrum of drug safety

Author: E. A. M. Gale

Published in: Diabetologia | Issue 10/2009

Login to get access

Excerpt

Drugs for health generate wealth, and wealth drives the diabetes roadshow. Without it, the subsidised seasonal migrations to our big meetings would grind to a halt, and the KOLs (Key Opinion Leaders, for the uninitiated) would all be driving a different brand of car. Given that the USA absorbs one in every two drug dollars expended on this planet, it is no surprise that the American Diabetes Association (ADA) meeting provides the premier catwalk upon which the latest drug models strut their stuff. The meeting is followed by a series of debriefing sessions in which big names in diabetes are courted by investors eager to learn the latest gossip. …
Literature
1.
2.
Smith U, Gale EAM (2009) Does diabetes therapy influence the risk of cancer? Diabetologia 52:1699–1708PubMedCrossRef
3.
Nissen SE, Wolski K (2007) Effect of rosiglitazone on the risk of myocardial infarction. N Engl J Med 356:2457–2471PubMedCrossRef
4.
Nathan DM (2007) Finding new treatments for diabetes—how many, how fast, how good? N Engl J Med 356:437–440PubMedCrossRef
5.
6.
Nathan DM, Buse JB, Davidson MB et al (2009) Medical management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 52:17–30PubMedCrossRef
7.
8.
Gale EAM, Beattie SD, Jinghui Hu, Koivisto V, Tan MH (2007) Recruitment to a clinical trial improves glycemic control in patients with diabetes. Diabetes Care 30:2989–2992PubMedCrossRef
9.
10.
11.
12.
13.
Galbraith JK (1993) American capitalism. The concept of countervailing power. Transaction Publishers, Edison. Originally published in 1952 by Houghton Mifflin, Boston
14.
Stricker BH, Psaty BM (2004) Detection, verification and quantification of adverse drug reactions. BMJ 329:44–47PubMedCrossRef
15.
16.
McGoey L, Jackson E (2008) Seroxat and the suppression of clinical trial data: regulatory failure and the uses of legal ambiguity. J Med Ethics 35:107–112CrossRef
17.
18.
Committee on the Assessment of the US Drug Safety System (2007) The future of drug safety. Institute of Medicine of the National Academies, National Academies Press, Washington
19.
Rosenstock J, Fonseca V, McGill JB et al (2009) Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study. Diabetologia. doi:10.​1007/​s00125-009-1415-7
20.
Gottlieb S (2005) Opening Pandora’s pillbox: using modern information tools to improve drug safety. Health Aff (Millwood) 24:938–948CrossRef
21.
22.
Tripathy NR, Basha S, Jain R, Shetty S, Ramachandran A (2008) Exenatide and acute pancreatitis. J Assoc Phys India 56:987–988
23.
24.
25.
Ahmed SR, Swann J (2008) Exenatide and rare adverse events. N Engl J Med 358:1969–1970CrossRef
26.
Exenatide (marketed as Byetta) Acute pancreatitis. FDA drug safety newsletter, Winter (2008). 12–14
27.
Stephens JW, Bain SC (2007) Safety and adverse effects associated with GLP-1 analogues. Expert Opin Drug Saf 6:417–422PubMedCrossRef
28.
Bain SC, Stephens JW (2008) Exenatide and pancreatitis: an update. Expert Opin Drug Saf 7:643–644PubMedCrossRef
29.
Noel RA, Braun DK, Patterson RE, Bloomgren G (2009) Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study. Diabetes Care 32:834–838PubMedCrossRef
30.
Dore DD, Seeger JD, Chan KA (2009) Use of a claims-based active drug surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin 25:1019–1027PubMedCrossRef
31.
Pocock N (2009) MHRA drug safety update: Risk of severe pancreatitis and renal failure with exenatide (Byetta®). Drug safety update, Volume 2, Issue 8
32.
33.
34.
35.
Illich I (1976) Limits to medicine. Medical nemesis: the expropriation of health. Marion Boyars, London
36.
Todd A, La Cecla F (2002) Ivan Illich: obituary. The Guardian, Monday 9 December
37.
Woloshin S, Schwartz LM, Welch HG (2008) Know your chances. Understanding health statistics. University of California Press, Berkeley
Metadata
Title
Collateral damage: the conundrum of drug safety
Author
E. A. M. Gale
Publication date
01-10-2009
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 10/2009
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-009-1491-8

Other articles of this Issue 10/2009

Diabetologia 10/2009 Go to the issue

Article

Impaired regulation of the TNF-α converting enzyme/tissue inhibitor of metalloproteinase 3 proteolytic system in skeletal muscle of obese type 2 diabetic patients: a new mechanism of insulin resistance in humans

Article

Perinatal survivin is essential for the establishment of pancreatic beta cell mass in mice

Article

Insulin resistance, beta cell dysfunction and visceral adiposity as predictors of incident diabetes: the Insulin Resistance Atherosclerosis Study (IRAS) Family Study

Letter

Copper chelation as a potential treatment for left-ventricular hypertrophy in type 2 diabetes

Letter

The longest ever randomised controlled trial of insulin glargine: study design and HbA1c findings

Article

Leptin prevents the metabolic effects of adiponectin in L6 myotubes
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits